Docket Number:12A-950101, 12A-950101B
Inventor:Chih-Cheng Chen, Shyh-Jer Huang, Yi-Wen Lin
IP Status:Issued US7,598,039B2、US7,838,005B2、TWI333978
Abstract:
Insulin resistance is a quite common state associated with aging and fueled by obesity. In most patients, insulin resistance can be detected long before the type II diabetes. Insulin resistance is also often related to central obesity, hypertension, polycystic ovarian syndrome, dyslipidemia, atherosclerosis, or syndrome X. Therefore controlling the age-dependent insulin resistance is an effective approach to prevent and correct the type II diabetes and many other human disease states. We have discovered a novel pathway, which is involved in the age-dependent insulin resistance. By blocking the key molecule we have discovered, it is promising to control the insulin resistance syndromes.
Fields of Application:
- Age-dependent insulin resistance & glucose intolerance
- Type II diabetes
- Obesity
- Metabolic syndrome
Advantages when compared to the existing technologies:
Control of insulin signaling pathways and fat reduction are the hallmark of the strategies to control and/or prevent obesity and type II diabetes. However, current approaches often emphasize the treated efficacy and ignore the age-dependent issue, which is more clinically relevant. Our strategy is focused on controlling the age-dependent insulin resistance and maintaining a young status of insulin signaling, so that we can prevent both fat accumulation and many unwanted side effects on fat reduction.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
